Chimeric antigen receptor T cell (CAR-T cell) activation via switch molecule (CAR-T cell activation (via switch molecule))

Chimeric antigen receptor T cell activation refers to the process by which genetically engineered T cells, expressing a synthetic chimeric antigen receptor, are activated upon binding to their target antigen on diseased cells. The chimeric antigen receptor is an artificial fusion protein that combines an extracellular domain for specific recognition of a surface molecule on target cells with intracellular signaling domains that trigger robust T-cell activation and cytotoxic function. This technology underpins CAR-T cell therapies, which have shown significant efficacy in treating certain cancers such as B-cell leukemias and lymphomas. The term "activation via switch molecule" suggests the use of an intermediary or modular system—sometimes called "switchable" or "universal" CARs—whereby the activity of the engineered T cells can be controlled or redirected using externally administered molecules. However, this phrase does not refer to a single molecular entity but rather describes a therapeutic strategy or platform involving multiple components. Therefore, "Chimeric antigen receptor T cell activation via switch molecule" is not itself a canonical molecular target but rather describes an engineered cellular process and therapeutic approach. The actual targets in these systems are typically specific tumor-associated antigens recognized by the extracellular domain of the chimeric receptors; examples include CD19 for B-cell malignancies[3][6]. Safety concerns with this approach include cytokine release syndrome and neurotoxicity due to excessive immune activation[1]. In summary, while chimeric antigen receptors themselves are synthetic proteins classified as receptors, "CAR-T cell activation via switch molecule" does not correspond to a discrete molecular target but instead refers to how these therapies can be modulated using external agents—a concept relevant in advanced immunotherapy design.

Other names

CAR-T cell activationChimeric antigen receptor T-cell signalingCAR T-cell therapy mechanism

Redirected cytotoxicity via engineered recognition of tumor antigens[3][6]